The decision of the international company Boehringer Ingelheim to stop the import of the drug Micardis to Russia will not affect the availability of drugs containing the active ingredient telmisartan in the country. This has been reported TASS In Roszdravnadzor.
“On July 13 last year, LLC Boehringer Ingelheim officially notified Roszdravnadzor that it will stop the supply of Micardis and Micardisplus to Russia from January 2023.”
“This decision does not affect the availability of telmisartan medicines for patients,” Roszdravnadzor said.
early september reportedIt is stated that Russia more than doubled its imports of pharmaceutical products from Brazil in the seven months of 2023.
We are talking about drugs such as Fiasp, Protafan and Actrapid, which are popular and in demand drugs in the treatment of diabetes. Certain types of pharmaceuticals, oral and dental hygiene products, and essential oils were also purchased.
Formerly in the State Duma contributed Free medicine bill for Russians
Source: Gazeta
Ben Stock is a business analyst and writer for “Social Bites”. He offers insightful articles on the latest business news and developments, providing readers with a comprehensive understanding of the business world.